Myeloid Leukemia

Diagnosis of AML1-MTG8 (ETO)-Positive AML 161
4. Gabert, J., Beillard, E., van der Velden, V. H. J., et al. (2003) Standardization and
quality control studies of ’real-time’ quantitative reverse transcriptase polymerase
chain reaction of fusion gene transcripts for residual disease detection in leukemia—A
Europe Against Cancer Program. Leukemia 17, 2318–2357.
5. Chomczynski, P. and Sacchi, N. (1987) Single-step method of RNA isolation by
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162,
156–159.
6. Nucifora, G., Larson, R. A., and Rowley, J. D. (1993) Persistence of the 8;21
translocation in patients with acute myeloid leukemia type M2 in long-term
remission. Blood 82, 712–715.
7. Kusec, R., Laczika, K., Knobl, P., et al. (1994) AML1/ETO fusion mRNA can be
detected in remission blood samples of all patients with t(8;21) acute myeloid
leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia
8, 735–739.
8. Saunders, M. J., Tobal, K., and Liu Yin, J. A. (1994) detection of t(8;21) by reverse
transcriptase polymerase chain reaction in patients in remission of acute
myeloid leukemia type M2 after chemotherapy or bone marrow transplantation.
Leuk. Res. 18, 891–895.
9. Morschhauser, F., Cayuela, J. M., Martini S., et al. (2000) Evaluation of minimal
residual disease using reverse transcriptase polymerase chain reaction in t(8 ;21)
acute myeloid leukemia : a multicentre study of 51 patients. J. Clin. Oncol. 18,
788–794.
10. Lion, T. and Kidd, V. (chairmen). (1998) Debate round-table: appropriate controls
for RT-PCR. Leukemia 12, 1983–1993.
11. Tobal, K., Newton, J., Macheta, M., et al. (2000) Molecular quantitation of minimal
residual disease in acute myeloid leukemia with t(8;21) can identify patients
in durable remission and predict clinical relapse. Blood 95, 815–819.